However, among RA patients treated with b/tsDMARDs, there was a significant effect of both treatment (P = 0.022) and PtGA (P = 0.005) on anti-PTX3 antibodies, with mean titres significantly higher (P = 0.025) in patients treated with TNFi (0.135, SE = 0.911; reference) compared with non-TNFi bDMARDs (abatacept + tocilizumab; 0.092, SE = 0.897) and JAKi (0.131, SE = 0.868) (Supplementary Fig. S1, available at Rheumatology online). This evidence concerns the gene PTX3 and rheumatoid arthritis.